Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

Australia & Canada — Health Canada

11 shared events · Importance 5 · Last updated Sep 23, 2026

Importance
5
Shared Events
11
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
49
Business
Australia: Australia is a key international market where MedMira is initiating regulatory approval for its Canada — Health Canada-approved products under a Mutual Recognition Agreement, aiming to accelerate market entry and expand its international presence.
Canada — Health Canada: Canada — Health Canada is the regulatory body providing initial feedback to MedMira regarding the approval process for its Multiplo Complete Syphilis Antibody Test.
Jun 30, 2026 · 6 articles
46
Domestic
Australia: Australia is mentioned as a peer jurisdiction that has created a regulated framework for prescribing psilocybin and MDMA, serving as a comparative example for Canada.
Canada — Health Canada: Canada — Health Canada is the government agency responsible for drug approval processes in Canada. Bill C-286 seeks to streamline its Special Access Program for psilocybin and psilocin, which has been criticized for slow and unpredictable approvals.
Jun 16, 2026 · 6 articles
45
Business
Australia: Australia is currently a commercial market where Optimi Health's 5mg psilocybin capsules are prescribed to patients for treatment-resistant depression, demonstrating an existing successful market for the company's products.
Canada — Health Canada: Canada — Health Canada issued the Drug Establishment Licence (DEL) to Optimi Health, authorizing the company's manufacturing, packaging, labeling, testing, storage, and distribution of controlled drug products.
Jun 02, 2026 · 25 articles
40
Business
Australia: Australia is the recipient country for Optimi Health's psilocybin capsules, providing a regulated market for the treatment of treatment-resistant depression and setting a model for psychedelic medicine use.
Canada — Health Canada: Canada — Health Canada issued the Drug Establishment Licence for Optimi Health's facility and the export authorization for the psilocybin shipment to Australia, regulating the production and export of these controlled substances.
Jun 29, 2026 · 12 articles
27
Tech
Australia: Australia is one of the countries where the Volt PFA System is approved and available, and where part of the VOLT-AF IDE trial was conducted.
Canada — Health Canada: Canada — Health Canada authorized the Volt PFA System in April 2026, enabling its use in Canada and paving the way for this first procedure.
Sep 15, 2026 · 6 articles
24
Tech
Australia: Australia is a market where Optimi Health Corp.'s 5mg psilocybin formulation is already commercially prescribed for treatment-resistant depression under the country's Authorized Prescriber Scheme.
Canada — Health Canada: Canada — Health Canada has issued a Drug Establishment License (DEL) to Optimi Health Corp., allowing it to produce and distribute regulated psychedelic drug products.
Jun 16, 2026 · 11 articles
24
Tech
Australia: Australia is mentioned as a market where Optimi's products are prescribed under the Authorized Prescriber Scheme, indicating existing international reach. It is not directly involved in the trial.
Canada — Health Canada: Canada — Health Canada authorized the clinical trial, enabling Optimi to proceed with the study. Its regulatory oversight is critical for the trial's legitimacy and future market authorization.
Sep 10, 2026 · 15 articles
22
Business
Australia: Australia previously approved WYNZORA, but is not directly affected by the Canadian launch.
Canada — Health Canada: Canada — Health Canada approved WYNZORA in December 2025, a regulatory prerequisite for the launch.
Aug 20, 2026 · 6 articles
21
Business
Australia: Optimi's products are prescribed to patients in Australia under the Authorized Prescriber Scheme, representing a current market for its psychedelic therapies.
Canada — Health Canada: The regulator authorized prior trials led by Dr. Blough and will interact with Optimi on future trial applications and oversight.
Sep 22, 2026 · 7 articles
17
Business
Australia: Australia is cited as a market where Optimi Health products are prescribed to patients under the Authorized Prescriber Scheme, illustrating the company's international reach.
Canada — Health Canada: Canada — Health Canada is referenced as the licensing authority under which Optimi Health manufactures GMP-grade psychedelic drug products; no new regulatory action is involved in this event.
Sep 08, 2026 · 6 articles
0
Business
Jan 26, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Australia and Canada — Health Canada interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.